REGN

ACCE thesis

Regeneron develops and commercializes medicines for cancer, eye diseases, and inflammatory conditions, with blockbuster drugs Eylea generating $6 billion annually and Dupixent hitting $11.6 billion in 2023 sales. The company's proprietary VelociSuite platform accelerates drug discovery by producing fully human antibodies in genetically modified mice, giving them a structural advantage in developing safer, more effective treatments. Linvoseltamab, their CD3xBCMA bispecific antibody for multiple myeloma, shows 71% response rates in heavily pre-treated patients and could launch by 2025 with peak sales potential exceeding $3 billion. Trading at 14.3x forward earnings with multiple late-stage assets advancing through trials, REGN offers exposure to both established cash cows and a pipeline that historically converts at twice the industry average. The stock has lagged biotech peers by 15% over the past year despite accelerating Dupixent growth in new indications like COPD.

• moderate
  Earnings declining despite revenue growth

  EPS down 7.2% YoY and QoQ while revenue grew 19%, signaling rising costs or margin pressure squeezing profitability.
• moderate
  ACCE score deteriorating

  Score dropped 7 points in 90 days (71→64), with Momentum at only 45/100, suggesting weakening price trend and sentiment.
• moderate
  Insider selling, no buying

  Last 10 disclosed transactions show $4.45M in sales and zero buys, a cautious signal from those closest to the business.

Snapshot